|
rs61764370
|
|
Malignant Neoplasms
|
|
0.050 |
GeneticVariation
|
BEFREE |
These results indicated that genotype.GT/GG of rs61764370 was not a genetic susceptible risk factor for cancer, and rs61764370 could not be used as a biomarker for estimating cancer risk in Caucasian population.
|
27461636 |
2017 |
|
rs61764370
|
|
Malignant Neoplasms
|
|
0.050 |
GeneticVariation
|
BEFREE |
We conclude that KRAS rs61764370 polymorphism is significantly associated with risk and prognosis of gallbladder malignancy in this endemic belt.
|
27620744 |
2016 |
|
rs61764370
|
|
Malignant Neoplasms
|
|
0.050 |
GeneticVariation
|
BEFREE |
rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers.
|
25940428 |
2016 |
|
rs61764370
|
|
Malignant Neoplasms
|
|
0.050 |
GeneticVariation
|
BEFREE |
These results suggest that the cancer-associated rs61764370 variant exerts a biological effect not through transcriptional modulation of KRAS but rather by tuning the expression of the microRNA let-7.
|
24282149 |
2014 |
|
rs61764370
|
|
Malignant Neoplasms
|
|
0.050 |
GeneticVariation
|
BEFREE |
We previously identified a functional variant in a let-7 microRNA (miRNA) complementary site in the 3'-untranslated region of the KRAS oncogene (rs61764370) which is associated with cancer.
|
21435948 |
2011 |
|
rs61764370
|
|
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
These results indicated that genotype.GT/GG of rs61764370 was not a genetic susceptible risk factor for cancer, and rs61764370 could not be used as a biomarker for estimating cancer risk in Caucasian population.
|
27461636 |
2017 |
|
rs61764370
|
|
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
We conclude that KRAS rs61764370 polymorphism is significantly associated with risk and prognosis of gallbladder malignancy in this endemic belt.
|
27620744 |
2016 |
|
rs61764370
|
|
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
These results suggest that the cancer-associated rs61764370 variant exerts a biological effect not through transcriptional modulation of KRAS but rather by tuning the expression of the microRNA let-7.
|
24282149 |
2014 |
|
rs61764370
|
|
Primary malignant neoplasm
|
|
0.040 |
GeneticVariation
|
BEFREE |
We previously identified a functional variant in a let-7 microRNA (miRNA) complementary site in the 3'-untranslated region of the KRAS oncogene (rs61764370) which is associated with cancer.
|
21435948 |
2011 |
|
rs61764370
|
|
Colorectal Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Eight miRSNPs (rs1804191, rs397768, rs41116 in APC; rs1137918, s227091, rs4585 in ATM; rs712, rs1137282, rs61764370 in KRAS; rs8674 in PARP1 and rs16950113 in SMAD7) were tested for their association with CRC risk in a case-control study (1111 cases and 1469 healthy controls).
|
29048575 |
2017 |
|
rs61764370
|
|
Colorectal Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
A single-nucleotide polymorphism (rs61764370, T > G base substitution) in the let-7 complementary site 6 (LCS-6) of KRAS mRNA has been shown to predict prognosis in early-stage colorectal cancer (CRC) and benefit from anti-epidermal growth factor receptor monoclonal antibodies in metastatic CRC.
|
26162609 |
2015 |
|
rs61764370
|
|
Colorectal Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
A PubMed search was conducted to identify all studies reporting on KRAS let-7 microRNA-binding site polymorphism (LCS6; rs61764370) and colorectal cancer outcome.
|
24890702 |
2014 |
|
rs61764370
|
|
Malignant neoplasm of ovary
|
|
0.030 |
GeneticVariation
|
BEFREE |
These data exclude the possibility of an association between rs61764370 and a clinically significant risk of ovarian cancer or of familial ovarian cancer.
|
21385923 |
2011 |
|
rs61764370
|
|
ovarian neoplasm
|
|
0.030 |
GeneticVariation
|
BEFREE |
Recently, a variant allele in the 3'UTR of the KRAS gene (rs61764370 T>G) was shown to be associated with an increased risk for developing non-small cell lung cancer, as well as ovarian cancer, and was most enriched in ovarian cancer patients from hereditary breast and ovarian cancer families.
|
20676756 |
2011 |
|
rs61764370
|
|
ovarian neoplasm
|
|
0.030 |
GeneticVariation
|
BEFREE |
These data exclude the possibility of an association between rs61764370 and a clinically significant risk of ovarian cancer or of familial ovarian cancer.
|
21385923 |
2011 |
|
rs61764370
|
|
Carcinoma, Ovarian Epithelial
|
|
0.030 |
GeneticVariation
|
BEFREE |
Recently, a variant allele in the 3'UTR of the KRAS gene (rs61764370 T>G) was shown to be associated with an increased risk for developing non-small cell lung cancer, as well as ovarian cancer, and was most enriched in ovarian cancer patients from hereditary breast and ovarian cancer families.
|
20676756 |
2011 |
|
rs61764370
|
|
Carcinoma, Ovarian Epithelial
|
|
0.030 |
GeneticVariation
|
BEFREE |
These data exclude the possibility of an association between rs61764370 and a clinically significant risk of ovarian cancer or of familial ovarian cancer.
|
21385923 |
2011 |
|
rs61764370
|
|
Malignant neoplasm of ovary
|
|
0.030 |
GeneticVariation
|
BEFREE |
Recently, a variant allele in the 3'UTR of the KRAS gene (rs61764370 T>G) was shown to be associated with an increased risk for developing non-small cell lung cancer, as well as ovarian cancer, and was most enriched in ovarian cancer patients from hereditary breast and ovarian cancer families.
|
20676756 |
2011 |
|
rs61764370
|
|
ovarian neoplasm
|
|
0.030 |
GeneticVariation
|
BEFREE |
In this study, we investigated a hypothesized association between an increased risk of OC and a variant allele of KRAS at rs61764370, referred to as the KRAS-variant, which disrupts a let-7 miRNA binding site in this oncogene.
|
20647319 |
2010 |
|
rs61764370
|
|
Carcinoma, Ovarian Epithelial
|
|
0.030 |
GeneticVariation
|
BEFREE |
In this study, we investigated a hypothesized association between an increased risk of OC and a variant allele of KRAS at rs61764370, referred to as the KRAS-variant, which disrupts a let-7 miRNA binding site in this oncogene.
|
20647319 |
2010 |
|
rs61764370
|
|
Malignant neoplasm of ovary
|
|
0.030 |
GeneticVariation
|
BEFREE |
In this study, we investigated a hypothesized association between an increased risk of OC and a variant allele of KRAS at rs61764370, referred to as the KRAS-variant, which disrupts a let-7 miRNA binding site in this oncogene.
|
20647319 |
2010 |
|
rs61764370
|
|
Endometriosis
|
|
0.020 |
GeneticVariation
|
BEFREE |
Lack of an Association between a Polymorphism in the KRAS 3' Untranslated Region (rs61764370) and Endometriosis in a Large European Case-Control Study.
|
31185482 |
2019 |
|
rs61764370
|
|
Squamous cell carcinoma of the head and neck
|
|
0.020 |
GeneticVariation
|
BEFREE |
This pilot study provides preliminary evidence supporting genetic variation of EGFR (rs2227983), KRAS (rs61764370) and FCGR2A (rs180127) as useful biomarkers for predicting reduced skin toxicity in HNSCC patients treated with a cetuximab-based therapy.
|
27938998 |
2016 |
|
rs61764370
|
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers.
|
25940428 |
2016 |
|
rs61764370
|
|
Malignant neoplasm of breast
|
|
0.020 |
GeneticVariation
|
BEFREE |
rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers.
|
25940428 |
2016 |